These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29274493)

  • 21. Synthesis, molecular docking study and biological evaluation of new pyrrole scaffolds as potential antitubercular agents for dual targeting of enoyl ACP reductase and dihydrofolate reductase.
    Mahnashi MH; Avunoori S; Gopi S; Shaikh IA; Saif A; Bantun F; Faidah HS; Alhadi AA; Alshehri JH; Alharbi AA; S R PK; Joshi SD
    PLoS One; 2024; 19(5):e0303173. PubMed ID: 38739587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
    Bastien D; Ebert MC; Forge D; Toulouse J; Kadnikova N; Perron F; Mayence A; Huang TL; Vanden Eynde JJ; Pelletier JN
    J Med Chem; 2012 Apr; 55(7):3182-92. PubMed ID: 22424148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
    Gangjee A; Lin X; Queener SF
    J Med Chem; 2004 Jul; 47(14):3689-92. PubMed ID: 15214795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.
    Kumar A; Siddiqi MI
    J Mol Graph Model; 2008 Nov; 27(4):476-88. PubMed ID: 18829358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.
    Srinivasan B; Tonddast-Navaei S; Skolnick J
    Eur J Med Chem; 2015 Oct; 103():600-14. PubMed ID: 26414808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference ¹H-NMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives.
    Mohebbi S; Falcón-Pérez JM; González E; Millet O; Mato JM; Kobarfard F
    Chem Pharm Bull (Tokyo); 2012; 60(1):70-8. PubMed ID: 22223377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors.
    Zhou X; Lin K; Ma X; Chui WK; Zhou W
    Eur J Med Chem; 2017 Jan; 125():1279-1288. PubMed ID: 27886545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
    Gangjee A; Elzein E; Queener SF; McGuire JJ
    J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
    Ewida MA; Ewida HA; Ahmed MS; Allam HA; ElBagary RI; George RF; Georgey HH; El-Subbagh HI
    Bioorg Chem; 2021 Oct; 115():105205. PubMed ID: 34329992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of reactivity of cyanoacetohydrazonoethyl-N-ethyl-N-methyl benzenesulfonamide: preparation of novel anticancer and antimicrobial active heterocyclic benzenesulfonamide derivatives and their molecular docking against dihydrofolate reductase.
    Debbabi KF; Al-Harbi SA; Al-Saidi HM; Aljuhani EH; Abd El-Gilil SM; Bashandy MS
    J Enzyme Inhib Med Chem; 2016; 31(sup4):7-19. PubMed ID: 27557134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological validation of dihydrofolate reductase as a drug target in
    Aragaw WW; Negatu DA; Bungard CJ; Dartois VA; Marrouni AE; Nickbarg EB; Olsen DB; Warrass R; Dick T
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0071723. PubMed ID: 38018963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
    Dias MV; Tyrakis P; Domingues RR; Paes Leme AF; Blundell TL
    Structure; 2014 Jan; 22(1):94-103. PubMed ID: 24210757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
    Santa Maria JP; Park Y; Yang L; Murgolo N; Altman MD; Zuck P; Adam G; Chamberlin C; Saradjian P; Dandliker P; Boshoff HIM; Barry CE; Garlisi C; Olsen DB; Young K; Glick M; Nickbarg E; Kutchukian PS
    ACS Chem Biol; 2017 Sep; 12(9):2448-2456. PubMed ID: 28806050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
    Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
    J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the ability of dihydropyrimidine-5-carboxamide and 5-benzyl-2,4-diaminopyrimidine-based analogues for the selective inhibition of L. major dihydrofolate reductase.
    Bibi M; Qureshi NA; Sadiq A; Farooq U; Hassan A; Shaheen N; Asghar I; Umer D; Ullah A; Khan FA; Salman M; Bibi A; Rashid U
    Eur J Med Chem; 2021 Jan; 210():112986. PubMed ID: 33187806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.